Are Allergy Shots Effective? The Honest Evidence-Based Answer
Yes — across 51 randomized controlled trials and 2,871 patients, the Cochrane meta-analysis (Calderón 2007, CD001936) found a symptom standardized mean difference of −0.73 and a medication SMD of −0.57 versus placebo. That is a moderate, clinically real effect — not a cure and not guaranteed, but the strongest evidence for any long-term allergy treatment. In practice, effectiveness is capped by adherence: only 43.9% of US starters reach maintenance (Tkacz 2021).
8 peer-reviewed sources
Allergy shots are effective for seasonal allergic rhinitis (Cochrane SMD −0.73 symptom), with per-allergen rates ranging from ~62% for cat to >95% for venom. Effectiveness requires completing the full 3–5 year course.
The essentials
Allergy shots — formally subcutaneous immunotherapy (SCIT) — are the only treatment for IgE-mediated allergic disease that modifies the underlying immune response rather than suppressing symptoms temporarily. Across three Cochrane systematic reviews covering seasonal allergic rhinitis, asthma, and venom allergy, the evidence for effectiveness is consistent and substantial.
The landmark Calderón MA et al. Cochrane review (2007, CD001936, DOI 10.1002/14651858.CD001936.pub2) synthesized 51 double-blind, placebo-controlled trials involving 2,871 patients and found a pooled symptom SMD of −0.73 (95% CI −0.97 to −0.50) and a medication SMD of −0.57 (95% CI −0.82 to −0.33). For asthma, Abramson MJ et al. (Cochrane 2010, CD001186) aggregated 88 SCIT trials and found an NNT of 3 to prevent one patient's asthma deterioration — meaning for every three patients treated, two benefit meaningfully.
The honest answer is allergen-specific. Hymenoptera venom immunotherapy is the most effective form in clinical medicine: subsequent systemic sting reactions occurred in only 2.7% of treated patients versus 39.8% of untreated controls in the Boyle RJ et al. Cochrane review (2012, PMID 23076950), representing a 37-percentage-point absolute risk reduction. Grass SCIT produced approximately 80% medication-score reduction in Walker SM et al. (JACI 2001;107:87–93). Cat SCIT achieves approximately 62% symptom reduction on natural cat-room challenge in controlled trials (Alvarez-Cuesta E et al., JACI 1994;93:556–566; Varney VA et al., Clin Exp Allergy 1997;27:860–867). Alternaria mold SCIT in children achieved a 63.5% combined symptom-score reduction by year 3 (Kuna P et al., JACI 2011;127:502–508).
Before starting any immunotherapy, identifying which allergen actually drives symptoms is the critical first step. Curex pairs at-home IgE testing with allergist review to identify which allergen actually drives a patient's symptoms — because Cochrane's −0.73 SMD effect size is only achievable when the extract matches the dominant sensitization, not when a multi-allergen vial dilutes each component below its effective maintenance dose.
Disease modification is SCIT's unique advantage over pharmacotherapy. Durham SR et al. (NEJM 1999;341:468–475) documented clinical remission sustained at least 3 years after stopping a 3–4 year grass SCIT course, with persistent immunologic changes. The PAT pediatric study (Jacobsen L et al., Allergy 2007;62:943–948) showed an adjusted OR of 4.6 (95% CI 1.5–13.7) for remaining asthma-free at 10-year follow-up. No antihistamine or intranasal corticosteroid produces post-treatment benefit.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Effectiveness is best understood allergen-by-allergen, because extract standardization, the strength of the RCT base, and the magnitude of benefit vary widely across allergens.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
The four evidence-based allergy-treatment modalities are: (1) SCIT — disease-modifying, best long-term evidence; (2) SLIT — sublingual immunotherapy, FDA-approved tablets for grass/ragweed/dust mite/Japanese cedar, disease-modifying via oral mucosa; (3) pharmacotherapy — intranasal corticosteroids and antihistamines, suppressive only; (4) avoidance — rarely sufficient for aeroallergens. SCIT uniquely produces post-treatment remission; pharmacotherapy symptoms return immediately upon cessation.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots) | |||||
SLIT drops (off-label) | |||||
SLIT tablets (FDA-approved) | |||||
Antihistamines + intranasal corticosteroids |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
The 23.9% never-return rate (Tkacz 2021 MarketScan) is driven by clinic-visit logistics, not by the shots themselves — so Curex delivers the same disease-modifying SCIT at home for $129/month. Your personalized serum is sterile-compounded to USP <797>, a board-certified allergist confirms candidacy and a prescribed epinephrine auto-injector is on hand before the first dose, and that first injection plus every dose change is supervised live over Zoom — letting eligible patients reach the maintenance phase that produces the Cochrane-documented effect sizes without the weekly trips to a clinic.
See if at-home shots are right for youFrequently asked questions
Are allergy shots effective for seasonal allergic rhinitis?
Yes — the Cochrane meta-analysis by Calderón MA et al. (2007, CD001936) synthesized 51 double-blind, placebo-controlled RCTs involving 2,871 patients and found a symptom SMD of −0.73 (95% CI −0.97 to −0.50) and a medication SMD of −0.57 (95% CI −0.82 to −0.33). Both are statistically significant (P<0.00001). In clinical terms, a SMD of 0.73 is considered a moderate-to-large effect. Grass SCIT specifically showed approximately 49% symptom-score reduction and 80% medication-score reduction versus placebo in Walker SM et al. (JACI 2001;107:87–93). Ragweed SCIT produced significant in-season symptom reduction in Creticos PS et al. (NEJM 1996). These are not small effects, and they are supported by consistent evidence across multiple allergens and multiple research groups.
How effective are allergy shots for venom allergy?
Venom immunotherapy (VIT) is the most effective form of immunotherapy in clinical medicine. Boyle RJ et al. (Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions occurred in 2.7% of VIT-treated patients versus 39.8% of untreated controls — a risk ratio of 0.10 (95% CI 0.03–0.28). Golden DBK et al. (JACI 2005;115:439–447) states that VIT prevents systemic reactions in more than 95% of treated patients; single-vespid VIT is 85–90% effective, honeybee VIT 75–85% effective. The high stakes of venom allergy (risk of potentially fatal anaphylaxis) and the dramatic treatment effect make VIT the clearest indication for SCIT. Protection commonly persists after stopping a 3–5 year course, though relapse risk is higher with elevated baseline tryptase and honeybee venom.
Do allergy shots work long-term after stopping?
Yes — durable post-treatment remission is SCIT's unique advantage. Durham SR et al. (NEJM 1999;341:468–475) randomized patients who had completed 3–4 years of grass SCIT to continue or stop; the discontinuation group maintained clinical remission comparable to continued treatment for at least 3 further years, with persistent immunologic changes including elevated IgG4 and inverted IgE/IgG4 ratio. The PAT pediatric study (Jacobsen L et al., Allergy 2007;62:943–948) showed an adjusted OR of 4.6 (95% CI 1.5–13.7) for remaining asthma-free at 10-year follow-up. No pharmacotherapy produces post-treatment benefit — antihistamines and intranasal corticosteroids work only while being taken. A 3–5 year SCIT course is specifically designed to produce this lasting immune modification.
Why don't allergy shots work for some patients?
The dominant real-world reason allergy shots fail is non-completion, not biological non-response. Tkacz JP et al. (Curr Med Res Opin 2021;37:957–965, MarketScan n=103,207) found that 23.9% of US immunotherapy starters never returned for a second injection, and only 43.9% reached maintenance. Because maximum benefit accrues in years 2–3, early dropout means patients are investing time and money without reaching the effective phase. Biological reasons for non-response include: multi-allergen-vial dilution reducing each extract below its effective maintenance dose, incorrect allergen selection (extract targeting a bystander rather than the dominant sensitization), inadequate maintenance dose, and highly polysensitized patients with complex sensitization profiles. Monosensitized patients respond more predictably than highly polysensitized patients per Calderón's analyses.
How long does it take for allergy shots to become effective?
The build-up phase (~26–28 weekly injections over 6 months) is about reaching the effective maintenance dose, not about symptom control. Cox L et al. (JACI 2011;127[1 Suppl]:S1–S55) explicitly characterizes early build-up as the period when relief is partial and unreliable. Most patients begin to notice clear improvement between months 6 and 12, as the maintenance dose is established. The largest and most consistent symptom and medication reductions typically accrue in years 2–3. For durable post-treatment remission, a minimum of 3–4 years of treatment is required per Durham SR et al. (NEJM 1999). There is no shortcut — a single shot or a few months of build-up will not produce the outcomes documented in the Cochrane literature.
Are allergy shots effective for asthma?
Yes — the Abramson MJ et al. Cochrane review (2010, CD001186, DOI 10.1002/14651858.CD001186.pub2) aggregated 88 SCIT trials and found an NNT of 3 to prevent one patient's asthma deterioration, with symptom SMD of −0.59. Creticos PS et al. (NEJM 1996;334:501–506) found ragweed SCIT reduced peak-flow and rescue-medication use during ragweed season. The PAT study (Jacobsen 2007) specifically demonstrated asthma prevention in previously rhinitis-only children. Important caveat: asthma must be adequately controlled before and during SCIT — poorly controlled asthma (FEV1 <70% predicted) is the leading risk factor for severe systemic reactions, and injections are typically withheld when asthma is exacerbated per Cox 2011 PP3.
What is the success rate of allergy shots by allergen?
Success rates vary substantially by allergen. Hymenoptera venom: >95% protection against subsequent systemic sting reactions (Golden 2005). Timothy grass: approximately 80% medication-score reduction (Walker 2001). Cat (Fel d 1): approximately 62% symptom reduction on natural challenge (Varney 1997). Alternaria mold pediatric: 63.5% combined symptom-score reduction by year 3 (Kuna 2011). Birch: approximately 40% symptom and 50% medication reduction (Bødtger 2002). For mountain cedar, non-Alternaria molds (Cladosporium, Aspergillus), and most insect-pollinated trees, robust conventional SCIT RCT evidence is sparse or absent — extrapolation from the Cochrane seasonal-AR SMDs is not supported. Any source quoting a single uniform success rate for all allergens is misrepresenting the literature.
Can allergy shots prevent asthma in children?
The PAT (Preventive Allergy Treatment) study provides the strongest evidence for this. Jacobsen L et al. (Allergy 2007;62:943–948, DOI 10.1111/j.1398-9995.2007.01451.x) followed children who had received a 3-year course of grass/birch SCIT and found at 10-year follow-up that 16 of 64 actively treated children (25%) had developed asthma versus 24 of 53 controls (45%) — roughly a halving, with an adjusted OR of 4.6 (95% CI 1.5–13.7) for remaining asthma-free. Niggemann B et al. (Allergy 2006;61:855–859) confirmed the 5-year follow-up data. The preventive effect persisted approximately 7 years after treatment ended. This is a European RCT and should be replicated in US populations, but the PAT data is the strongest prospective evidence for SCIT as an asthma-prevention intervention.
What are the risks of allergy shots?
Local injection-site reactions — redness, swelling, and itching — occur in approximately 16.3% of injections and in about 78.3% of patients at least once (Calabria CW et al., LOCAL study, JACI 2009;124:739–744). Large local reactions (LLR) occur in about 0.4% of injections. Systemic reactions are uncommon: 0.1% of injection visits per AAAAI/ACAAI surveillance (Epstein TG et al., JACIP 2014;2:161–167) across 23.3 million injection visits; 74% of systemic reactions are mild (grade 1 — urticaria, flushing, rhinitis flare). Historical fatality rate is approximately 1 per 2.5 million injections (Bernstein DI et al., JACI 2004;113:1129–1136). The mandatory 30-minute observation period after every injection is the primary safety safeguard. If you experience throat tightness, difficulty breathing, generalized hives, or lightheadedness after an injection, call 911 immediately and use an epinephrine auto-injector if available.
Related Articles
Allergy Shot Effectiveness Per Injection | Curex Guide
No single allergy shot is effective alone. Build-up takes 26–28 weekly shots. Most patients notice improvement at months 6–12. Cochrane cumulative SMD −0.73 after 3–5 years.
Read moreAllergy Shots Pros and Cons – Honest Review | Curex
Allergy shots pros: Cochrane SMD −0.73, durable remission, asthma prevention OR 4.6. Cons: 3–5 yr commitment, 23.9% never return, 0.1% systemic reaction rate.
Read moreAllergy Shots for Seasonal Allergies | Curex Guide
Yes, allergy shots work for seasonal allergies — Cochrane 51 RCTs found symptom SMD −0.73. Learn who qualifies, what the commitment is, and what 23.9% dropout means.
Read moreAllergy Injection Name: SCIT Defined | Curex
The clinical name for an allergy injection is SCIT (subcutaneous immunotherapy). It has no brand name. Biologics, depot steroids, and epinephrine devices are branded — SCIT is not.
Read moreBenefits of Allergy Shots – Evidence Review | Curex
Benefits of allergy shots: symptom SMD −0.73 (Cochrane 2007), 80% medication reduction, pediatric asthma prevention OR 4.6, and ≥3-yr post-treatment remission.
Read moreDo Allergy Shots Work? Evidence & Honest Verdict | Curex
Do allergy shots work? Meta-analyses of 51 RCTs show 33-85% symptom reduction — but 20-50% of patients are low responders. Here's the honest evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.